St Andrews Research Repository

View Item 
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.

Sialic acid-binding protein Sp2CBMTD protects mice against lethal challenge with emerging influenza A (H7N9) virus

View/Open
Antimicrob._Agents_Chemother._2014_Govorkova_AAC.04431_14.pdf (3.444Mb)
Date
03/2015
Author
Govorkova, E.A.
Baranovich, T.
Marathe, B.M.
Yang, L.
Taylor, M.A.
Webster, R.G.
Taylor, G.L.
Connaris, H.
Keywords
R Medicine (General)
Metadata
Show full item record
Abstract
Compounds that target the cellular factors essential for influenza virus replication represent an innovative approach to antiviral therapy. Sp2CBMTD is a genetically engineered multivalent protein that masks sialic acid-containing cellular receptors on the respiratory epithelium, which are recognized by influenza viruses. Here, we evaluated the antiviral potential of Sp2CBMTD against lethal infection in mice with an emerging A/Anhui/1/2013 (H7N9) influenza virus and addressed the mechanistic basis of its activity in vivo. Sp2CBMTD was administered to mice intranasally as a single or repeated dose (0.1, 1, 10, or 100 μg) before (day −7, −3, and/or −1) or after (6 or 24 h) H7N9 virus inoculation. A single Sp2CBMTD dose (10 or 100 μg) protected 80% to 100% of the mice when administered 7 days before the H7N9 lethal challenge. Repeated Sp2CBMTD administration conferred the highest protection, resulting in 100% survival of the mice even at the lowest dose tested (0.1 μg). When treatment began 24 h after exposure to the H7N9 virus, a single administration of 100 μg of Sp2CBMTD protected 40% of the mice from death. The administration of Sp2CBMTD induced the pulmonary expression of proinflammatory mediators (interleukin-6 [IL-6], IL-1β, RANTES, monocyte chemotactic protein-1 [MCP-1], macrophage inflammatory protein-1α [MIP-1α], and inducible protein [IP-10]) and recruited neutrophils to the respiratory tract before H7N9 virus infection, which resulted in less pronounced inflammation and rapid virus clearance from mouse lungs. Sp2CBMTD administration did not affect the virus-specific adaptive immune response, which was sufficient to protect against reinfection with a higher dose of homologous H7N9 virus or heterologous H5N1 virus. Thus, Sp2CBMTD was effective in preventing H7N9 infections in a lethal mouse model and holds promise as a prophylaxis option against zoonotic influenza viruses.
Citation
Govorkova , E A , Baranovich , T , Marathe , B M , Yang , L , Taylor , M A , Webster , R G , Taylor , G L & Connaris , H 2015 , ' Sialic acid-binding protein Sp2 CBMTD protects mice against lethal challenge with emerging influenza A (H7N9) virus ' Antimicrobial Agents and Chemotherapy , vol 59 , no. 3 , pp. 1495-1504 . DOI: 10.1128/AAC.04431-14
Publication
Antimicrobial Agents and Chemotherapy
Status
Peer reviewed
DOI
http://dx.doi.org/10.1128/AAC.04431-14
ISSN
0066-4804
Type
Journal article
Rights
Copyright © 2015, American Society for Microbiology. All Rights Reserved
Description
This study was supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract no. HHSN266200700005C and HHSN272201400006C, by the American Lebanese Syrian Associated Charities (ALSAC), and by the UK Medical Research Council Biomedical Catalyst grant MR/L012847/1.
Collections
  • University of St Andrews Research
  • Biology Research
  • Biomedical Sciences Research Complex (BSRC) Research
URI
http://hdl.handle.net/10023/7379

Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

Advanced Search

Browse

All of RepositoryCommunities & CollectionsBy Issue DateNamesTitlesSubjectsClassificationTypeFunderThis CollectionBy Issue DateNamesTitlesSubjectsClassificationTypeFunder

My Account

Login

Open Access

To find out how you can benefit from open access to research, see our library web pages and Open Access blog. For open access help contact: openaccess@st-andrews.ac.uk.

How to submit research papers

The full text of research papers can be submitted to the repository via PURE, the University's research information system. For help see our guide: How to deposit in Pure.

Electronic thesis deposit

Help with deposit.

Repository help

For repository help contact: Digital-Repository@st-andrews.ac.uk.

Give Feedback

Cookie policy

This site may use cookies. Please see Terms and Conditions.

Usage statistics

COUNTER-compliant statistics on downloads from the repository are available from the IRUS-UK Service. Contact us for information.

© University of St Andrews Library

University of St Andrews is a charity registered in Scotland, No SC013532.

  • Facebook
  • Twitter